{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:02:04Z","timestamp":1790694124835,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In relapsed\/refractory (R\/R) diffuse large B\u2010cell lymphoma (DLBCL), a negative prognosis is frequently linked to heightened epigenetic heterogeneity. Chidamide, a selective histone deacetylase inhibitor, shows promise as a targeted therapy for R\/R DLBCL by targeting abnormal epigenetic changes associated with poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 27 ineligible patients with R\/R DLBCL participated in an open \u2014 label, single \u2014 arm study. Chidamide was administered orally at a dose of 30 mg twice weekly for one week during the induction monotherapy phase. The subsequent combination therapy phase involved oral chidamide at a dose of 20 mg twice weekly for two weeks, followed by a one\u2010week discontinuation period, in conjunction with intravenous R\u2010GDP every 21 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the cohort of 31 patients who underwent screening (median age: 67\u2009years), 27 were ultimately included in the study, with 14 individuals successfully completing six cycles of C\u2010R\u2010GDP treatment. The overall best objective response rate was determined to be 79.1% (95% CI: 75.1%\u201383.3%), comprising a complete response rate of 45.8% (95% CI: 41.6%\u201349.9%) and a partial response rate of 33.3% (95% CI: 29.3%\u201337.4%). Within the subgroup of 14 patients who completed the full treatment regimen, the best objective response rate reached 100%, with 71.4% achieving complete response (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) and 28.6% achieving partial response (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094). The median follow\u2010up period for these patients was 17.0\u2009months, ranging from 3.5 to 55\u2009months. Progression\u2010free survival was 5.9\u2009months and overall survival was 48.3\u2009months. Anemia was the most common adverse event, affecting all patients. Thrombocytopenia led to treatment interruption or dose reduction in 13 patients. Other common adverse events included hypocalcemia, hyponatremia, and hypokalemia. Three patients experienced grade 3 pneumonitis and one had grade 3 skin rash.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Chidamide combined with R\u2010GDP is a safe and effective treatment option for patients with R\/R DLBCL who are not eligible for autologous stem cell transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.70142","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:27:22Z","timestamp":1724909242000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chidamide plus R\u2010\n                    <scp>GDP<\/scp>\n                    for relapsed\/refractory diffuse large B\u2010cell lymphoma in patients ineligible for autologous transplantation: A prospective, single\u2010arm, phase\n                    <scp>II<\/scp>\n                    study"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3576","authenticated-orcid":false,"given":"Guang\u2010Liang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3346-4868","authenticated-orcid":false,"given":"Zu\u2010guang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine Nanjing Medical University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-7364","authenticated-orcid":false,"given":"Yizhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Department of Pathology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00389-w"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.09.002"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2015.01.003"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0358"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0439-6"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113942"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-6019"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2210-0"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B2200016"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0083"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04187-5"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001093"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.11947"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20587"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv106"},{"key":"e_1_2_13_19_1","first-page":"59","article-title":"Prognostic factors and efficacy of GDP\u2010R therapy in refractory\/relapsed diffuse large B\u2010cell lymphomas not eligible for high\u2010dose therapy","volume":"2","author":"Ghio F","year":"2015","journal-title":"J Cancer Metastasis Treat"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0211-2"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2979"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.111"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3056"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520936053"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14698"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280996"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0413"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.08"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S372783"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2136956"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145150"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01492"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70142","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.70142","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:48:27Z","timestamp":1790693307000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cam4.70142"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70142","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"2024-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70142"}}